SNPX - Wutah pendapatan taun lumaku Synaptogenix, Inc.

The success of bryostatin-1 will provide Synaptogenix, Inc. (SNPX) with absolute pricing power due to the highly inelastic demand for protein kinase C activation. Current year-over-year (TTM) sales dynamics illustrate the potential for cognitive function recovery through the creation of new neural connections, with the parameter value reaching 0.00. The company is currently restructuring its research to precisely verify the molecule's therapeutic properties.
Synaptogenix - rincian analitis lan metrik utama (SNPX)

This metric measures the percentage change in revenue over the last twelve months relative to the same period last year, allowing for an assessment of business scaling rates while excluding seasonal fluctuations. For Synaptogenix, Inc. (SNPX), which depends on clinical trial outcomes and external capital, the TTM annual revenue trend confirms a lack of operating income, shifting the fundamental valuation of the asset into the realm of pure venture risk.